Royalty Pharma Sustainability Profile
Royalty Pharma plc, headquartered in the United States, is a leading player in the biopharmaceutical industry, specialising in the acquisition of revenue-generating pharmaceutical royalties. Founded in 1996, the company has established itself as a pioneer in the royalty financing model, enabling innovation in drug development while providing capital to biopharmaceutical companies. With a diverse portfolio that includes royalties from some of the world's most successful therapies, Royalty Pharma stands out for its unique approach to funding and supporting drug development. The company operates primarily in North America and Europe, positioning itself as a key partner in the life sciences sector. Notable achievements include a robust market presence and a commitment to advancing healthcare through strategic investments in transformative therapies.
DitchCarbon Score
How does Royalty Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Royalty Pharma's score of 35 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Royalty Pharma's reported carbon emissions
In 2024, Royalty Pharma reported total carbon emissions of approximately 23.3 million kg CO2e, all of which fall under Scope 3 emissions, specifically from investments. This represents a decrease from the previous year's total of approximately 32.0 million kg CO2e in 2023. The company has not disclosed any Scope 1 or Scope 2 emissions data. Over the past few years, Royalty Pharma's emissions have shown a downward trend, with 2022 emissions recorded at approximately 19.6 million kg CO2e and 2021 emissions at approximately 18.4 million kg CO2e. Despite these reductions, the company has not set specific reduction targets or initiatives as part of its climate commitments. Royalty Pharma's emissions data is sourced directly from the company and does not cascade from any parent organisation. The company remains focused on its investment strategies while acknowledging the importance of addressing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | 18,445,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Royalty Pharma's Industry?
How Carbon Intensive is Royalty Pharma's Location?
Royalty Pharma's Scope 3 Categories Breakdown
Royalty Pharma's Scope 3 emissions, which decreased by 27% last year and increased by approximately 26% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Investments" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Royalty Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Royalty Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
